Jon Cuthbert

Precision BioSciences (NASDAQ:DTIL) announced Monday that it has achieved a $7.5 million clinical milestone under its licensing agreement with TG Therapeutics (NASDAQ:TGTX).

Australian Foreign Minister Penny Wong has advised the 115,000 Australians currently in the Middle East that commercial airlines remain the fastest route out of the region.

Web Travel Group (ASX:WEB) announced that CFO Tony Ristevski has withdrawn his resignation and will remain in his position, cancelling his planned move to electronic conveyancer PEXA (ASX:PXE).

Albion Resources (ASX:ALB) announced an expansion of its Western Australian gold portfolio by securing a binding option to acquire the Gidgee Gold Project.

The Australian Competition and Consumer Commission has escalated its scrutiny of Ampol's (ASX:ALD) proposed acquisition of EG Australia.

Sionna Therapeutics (NASDAQ:SION) entered 2026 with a substantial financial cushion, reporting $310.3 million in cash, cash equivalents, and marketable securities as of December 31, 2025.

Turning Point Brands (NYSE:TPB) delivered a strong conclusion to fiscal 2025, reporting fourth-quarter net income of $8.2 million, or 42 cents per share.

Kaspi.kz (NASDAQ:KSPI) delivered a robust set of fiscal 2025 results, reporting a 19% year-over-year increase in total revenue to KZT 3.1 trillion.

Vision Marine Technologies (NASDAQ:VMAR) disclosed significant growth within its direct-to-consumer rental division on Monday, reporting that its Portside Ventura, California operations saw a 167% year-over-year increase in excursion volume.

Belite Bio (NASDAQ:BLTE), a clinical-stage biopharmaceutical company focused on developing therapies for degenerative retinal diseases, today announced positive topline results from its pivotal Phase 3 DRAGON trial evaluating tinlarebant, an oral retinol binding protein 4 (RBP4) antagonist, for the treatment of adolescent Stargardt disease.